8-K: Veradigm Provides Preliminary Q1 2025 Financials and Secures New Debt Amidst Ongoing SEC Filing Delays

Veradigm Inc. announced preliminary unaudited financial results for Q1 2025, including revenue estimates and cash positions, while also detailing a new $100 million debt financing and reaffirming its 2025 fiscal year outlook, despite expecting to become current on SEC filings only in 2026.

Summary

• Veradigm reported preliminary unaudited GAAP Revenue for the fiscal quarter ended March 31, 2025, to be between $145 million and $147 million.
• Preliminary unaudited GAAP Revenue for the fiscal quarter ended March 31, 2024, was between $144 million and $146 million.
• Cash and equivalents as of March 31, 2025, were approximately $272 million, a decrease of $23 million from $295 million as of December 31, 2024.
• The cash decrease was attributed to approximately $13 million for prior acquisitions, $6 million for capital expenditures, and $4 million net outflows for operating activities, which included $15 million for Transaction and other expenses.
• Debt as of March 31, 2025, remained at approximately $208 million, consisting solely of the principal amount of the Company's 0.875% Convertible Senior Notes due 2027.
• The company recently completed a new senior secured debt financing of up to $100 million, with $75 million drawn at closing on June 18, 2025, and an additional $25 million accessible until December 18, 2026.
• Veradigm expects its total Debt as of June 30, 2025, to be $283 million, comprising the new $75 million borrowing and the $208 million convertible notes.
• If all holders of the 2019 convertible notes execute their repurchase option for cash on July 1, 2025, an additional $20 million would be required, totaling $228 million payable to convertible noteholders.
• The company reaffirmed its financial outlook for fiscal year 2025, expecting GAAP Revenue to be approximately flat compared to 2024, estimated between $583 million and $588 million.
• Net cash is expected to remain positive for fiscal year 2025.
• Veradigm closed deals with over $30 million in annual contract value in the first quarter of 2025, representing a 25% increase over the same period in 2024.
• The company anticipates becoming current in its SEC financial filings during 2026 and plans to subsequently seek to relist its common stock.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While the company reported positive commercial activity and secured new financing to bolster liquidity, the persistent delays in becoming current with SEC filings and the associated risks, including the OTC Expert Market listing and potential litigation, temper any strong positive outlook. The preliminary financial results are largely in line with expectations, but the cash burn for 'Transaction and other expenses' is a concern.

Positives

• Closed deals with over $30 million in annual contract value in Q1 2025, marking a 25% increase over Q1 2024, indicating strong commercial momentum.
• Secured new debt financing of up to $100 million, with $75 million already drawn, which strengthens the company's liquidity position.
• Reaffirmed the expectation for net cash to remain positive for fiscal year 2025.
• Preliminary Q1 2025 GAAP Revenue estimate ($145 million $147 million) is slightly higher than Q1 2024 ($144 million $146 million).

Negatives

• Cash and equivalents decreased by approximately $23 million in Q1 2025.
• The company expects to become current in its SEC financial filings only during 2026, indicating a prolonged delay in compliance.
• Veradigm's common stock is currently not trading on a national securities exchange and is listed on the OTC Expert Market.
• Approximately $15 million of cash outflows in Q1 2025 were attributed to 'Transaction and other expenses,' related to legal settlements, investigations, and restatement-related services.

Risks

• Risks relating to the Company's common stock not trading on a national securities exchange and deregistration from Section 12(b) of the Securities Exchange Act of 1934.
• A further material delay in the Company's financial reporting or ability to hold an annual meeting of stockholders.
• An inability of the Company to timely prepare its delinquent financial statements.
• Unanticipated factors or factors currently believed not to cause delay, including on remediation efforts and financial statement preparation, could cause additional delay or adjustments.
• The possibility that ongoing remediation work or the audit of financial statements for fiscal years ended December 31, 2023, or December 31, 2024, may identify additional errors and material weaknesses or other deficiencies in accounting practices.
• The likelihood that identified control deficiencies or future deficiencies will result in additional material weaknesses in the Company's internal control over financial reporting.
• Risks relating to the Company's voluntary disclosure to the SEC of information regarding the Audit Committee's investigation, the SEC's investigation, and ongoing information provision to the SEC.
• Risks relating to the putative securities class action lawsuit, putative stockholder derivative action, commercial litigation regarding financial statement representations, and any other future litigation or investigation related to internal control failures, the completed investigation, and reviews or related matters.
• Changes in the financial condition of the markets the Company serves.
• The Company's ability to hire qualified individuals for senior leadership roles on a permanent basis, including a chief executive officer and a chief financial officer.
• Risks associated with the Company's incurrence of additional debt and the terms and conditions of the new financing arrangement.

Future Outlook

Veradigm reaffirms its fiscal year 2025 GAAP Revenue outlook to be approximately flat compared to 2024, estimated between $583 million and $588 million. The company expects net cash to remain positive and anticipates becoming current in its SEC financial filings during 2026, after which it plans to seek relisting of its common stock.

Management Comments

• "The year started on a positive note by closing deals with over $30 million in annual contract value in the first quarter of 2025, a 25 percent increase over the same period in 2024." Tom Langan, Interim Chief Executive Officer.
• "We remain focused on building upon this momentum throughout the remainder of 2025 while also working toward becoming current in our SEC financial filings, which we expect to occur in 2026." Tom Langan, Interim Chief Executive Officer.
• "We recently completed a debt financing, strengthening our liquidity."

Industry Context

Veradigm operates in the healthcare data and technology solutions sector, a dynamic industry driven by digital transformation and data-driven insights. The company's focus on securing new deals and strengthening liquidity is consistent with the capital-intensive nature of technology development and market expansion in healthcare IT. However, the ongoing delays in SEC filings and the OTC Expert Market listing suggest significant internal challenges that could hinder its competitive positioning against more transparent and well-capitalized peers.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. The company's current status on the OTC Expert Market and ongoing SEC filing delays make direct comparison to publicly traded, fully compliant industry peers challenging.

Legal Proceedings

• Risks relating to the Company's voluntary disclosure to the SEC of certain information relating to the investigation by the Audit Committee of the Company's Board of Directors, the SEC's investigation, and the additional information the Company has continued to provide to the SEC based on discussions with the SEC.
• Risks relating to the putative securities class action lawsuit filed against the Company.
• Risks relating to the putative stockholder derivative action filed against the Company.
• Commercial litigation relating to the Company's representations regarding its financial statements.
• Any other future litigation or investigation relating to the Company's internal control failures, the completed investigation, and reviews or related matters.

Stakeholder Impact

• Shareholders: Continued uncertainty due to SEC filing delays and OTC Expert Market listing, potential for future relisting. Dilution risk from unvested restricted stock units. Impact from new debt financing terms.
• Employees: Potential impact from ongoing internal reviews and remediation efforts.
• Customers: Continued service and product delivery, as indicated by new deals closed.
• Creditors: New debt financing provides additional security for lenders, but existing convertible noteholders face potential repurchase options.
• Regulatory Authorities: Ongoing engagement with the SEC regarding financial reporting and investigations.

Next Steps

• Continue building commercial momentum throughout the remainder of 2025.
• Work toward becoming current in SEC financial filings, expected during 2026.
• Subsequently seek to relist its common stock on a national securities exchange.
• Host an investor conference call and webcast on June 24, 2025, to discuss the update.

Key Dates

Recommendation

Keywords

Healthcare technology, Healthcare data solutions, SEC filings, Financial results, Debt financing, Corporate governance, Risk management, Veradigm, MDRX, Preliminary earnings